Sleep expert Dr. Abhay Sharma talks about how Zepbound is now approved by the FDA for the treatment of moderate to severe ...

Aliso Viejo-based Apnea Sciences bought an industrial building in Irvine for $2.6 million. The 5,101 square foot building at ...

The global sleep apnea implants market is expected to grow from USD 317.1 million in 2023 to USD 1,158.1 million by 2033, at ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Awareness of sleep apnea and its relatively common and effective treatment has grown over the past three decades.

On the other hand, intermittent upper airway obstructions in OSAS during sleep would cause hypoxia with subsequent decrease in PaO 2 and increase in PaCO 2. The episodic vascular insufficiency may ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA) in ...

The first implant was done in Pittsburgh in Dec 2023 ... recently approved the first drug to treat obstructive sleep apnea. It’s a weight-loss drug called Zepbound (tirzepatide) which ...